An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 21 Oct 2016 Planned End Date changed from 1 May 2018 to 1 Feb 2019.
- 21 Oct 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Jul 2018.
- 21 Sep 2016 According to an Eisai Inc. media release, highlights of this trial will be presented at the 86th Annual Meeting of the American Thyroid Association (ATA) 2016.